Literature DB >> 17067733

Cholesterol dysfunction in neurodegenerative diseases: is Huntington's disease in the list?

Marta Valenza1, Elena Cattaneo.   

Abstract

Brain cholesterol is an essential component of cell membranes, and involved in a number of biological functions such as membrane trafficking, signal transduction, myelin formation and synaptogenesis. Given these widespread activities and the knowledge that all brain cholesterol derives from local synthesis, it is not surprising that dysfunctions in cholesterol synthesis, storage, transport and removal may lead to human brain diseases. Some of these diseases emerge as a consequence of genetic defects in the enzymes involved in cholesterol biosynthesis; in other cases, such as Alzheimer's disease, there is a link between cholesterol metabolism and the formation and deposition of amyloid-beta peptide. Emerging evidence indicates that changes in cholesterol synthesis may also occur in Huntington's disease, an inherited, autosomal dominant neurodegenerative disorder that primarily affects striatal neurons of the brain. We here provide an overview of the involvement of cholesterol in normal brain function and its impact on neurodegenerative diseases. In particular, we consider the available clinical, biological and molecular evidence indicating a potential dysregulation of cholesterol homeostasis in Huntington's disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17067733     DOI: 10.1016/j.pneurobio.2006.09.005

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  22 in total

1.  Lysosomal fusion and SNARE function are impaired by cholesterol accumulation in lysosomal storage disorders.

Authors:  Alessandro Fraldi; Fabio Annunziata; Alessia Lombardi; Hermann-Josef Kaiser; Diego Luis Medina; Carmine Spampanato; Anthony Olind Fedele; Roman Polishchuk; Nicolina Cristina Sorrentino; Kai Simons; Andrea Ballabio
Journal:  EMBO J       Date:  2010-09-24       Impact factor: 11.598

2.  NRIF is a regulator of neuronal cholesterol biosynthesis genes.

Authors:  Zeljka Korade; Rajappa S Kenchappa; Karoly Mirnics; Bruce D Carter
Journal:  J Mol Neurosci       Date:  2008-08-02       Impact factor: 3.444

3.  Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington's disease.

Authors:  Zhongmin Xiang; Marta Valenza; Libin Cui; Valerio Leoni; Hyun-Kyung Jeong; Elisa Brilli; Jiangyang Zhang; Qi Peng; Wenzhen Duan; Steven A Reeves; Elena Cattaneo; Dimitri Krainc
Journal:  J Neurosci       Date:  2011-06-29       Impact factor: 6.167

Review 4.  Sterols and sphingolipids: dynamic duo or partners in crime?

Authors:  Sonia Gulati; Ying Liu; Andrew B Munkacsi; Lisa Wilcox; Stephen L Sturley
Journal:  Prog Lipid Res       Date:  2010-04-01       Impact factor: 16.195

5.  Modeling cholesterol metabolism by gene expression profiling in the hippocampus.

Authors:  Christopher M Valdez; Clyde F Phelix; Mark A Smith; George Perry; Fidel Santamaria
Journal:  Mol Biosyst       Date:  2011-03-30

6.  Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes.

Authors:  Marta Valenza; Valerio Leoni; Joanna M Karasinska; Lara Petricca; Jianjia Fan; Jeffrey Carroll; Mahmoud A Pouladi; Elisa Fossale; Huu Phuc Nguyen; Olaf Riess; Marcy MacDonald; Cheryl Wellington; Stefano DiDonato; Michael Hayden; Elena Cattaneo
Journal:  J Neurosci       Date:  2010-08-11       Impact factor: 6.167

Review 7.  Cannabinoid receptor signalling in neurodegenerative diseases: a potential role for membrane fluidity disturbance.

Authors:  M Maccarrone; G Bernardi; A Finazzi Agrò; D Centonze
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

8.  MS/MS methodology to improve subcellular mapping of cholesterol using TOF-SIMS.

Authors:  Paul D Piehowski; Anthony J Carado; Michael E Kurczy; Sara G Ostrowski; Michael L Heien; Nicholas Winograd; Andrew G Ewing
Journal:  Anal Chem       Date:  2008-10-17       Impact factor: 6.986

9.  Niemann-Pick type C disease proteins: orphan transporters or membrane rheostats?

Authors:  Andrew B Munkacsi; Anthony F Porto; Stephen L Sturley
Journal:  Future Lipidol       Date:  2007-06

10.  Partial Amelioration of Peripheral and Central Symptoms of Huntington's Disease via Modulation of Lipid Metabolism.

Authors:  Jane Y Chen; Conny Tran; Lin Hwang; Gang Deng; Michael E Jung; Kym F Faull; Michael S Levine; Carlos Cepeda
Journal:  J Huntingtons Dis       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.